DOING MORE FOR PATIENTS WITH BD: METRE DWINGIN.

Arena Pharmaceuticals takes an "all in" approach to developing our investigational gastrointestinal drugs.*

We are bold enough to imagine treatments that result in better health outcomes and address unmet patient needs. Our pipeline is grounded in 2 decades of world-class, G-protein-coupled receptor discovery research.

VISIT ARENA PHARMACEUTICALS AT OUR VIRTUAL BOOTH



EXPLORE ARENA'S CLINICAL TRIALS

ACTIVE TRIALS

ELEVATE **RISE UP AGAINST UC**

ELEVATE UC is a Phase 3 clinical program evaluating the efficacy and safety of once-daily, oral etrasimod⁺ in patients with moderately to severely active ulcerative colitis (UC).

GLADIATOR — UC —— **BRINGING THE FIGHT TO UC**

GLADIATOR UC is a Phase 2, 52-week induction and maintenance study evaluating the safety and efficacy of once-daily, oral etrasimod⁺ in patients with moderately active UC.

CULTIVATE

ADDRESSING THE ROOT OF CD

CULTIVATE is a Phase 2/3 clinical trial evaluating the efficacy and safety of once-daily, oral etrasimod⁺ in patients with moderately to severely active Crohn's disease (CD).

VOYAGE **NAVIGATING A PATH**

FORWARD IN EOE

VOYAGE is a Phase 2 clinical trial program evaluating the safety and efficacy of etrasimod⁺ in patients with eosinophilic esophagitis (EoE).

*Arena is a clinical stage pharmaceutical company that does not have any medicines or products approved for use by any health authority. ⁺Etrasimod is an investigational drug and is not currently approved for use by any health authority.



PHARMACEUTICALS Care More. Act Differently.

Play our MOD-inspired game, Lymphoquest

Simply scan this QR code:



You can also access our augmented reality experience, see our science, and learn about our clinical trials.



© 2022 Arena Pharmaceuticals, Inc. Arena Pharmaceuticals, Arena, and Care More. Act Differently. are registered service marks of Arena Pharmaceuticals, Inc. All Rights Reserved. MLR-ALL-UC-0022